Fig. 3

AML cells transfer miR-4532 by exosomes to target LDOC1. a Venn diagram of the predicted target genes of miR-4532. b The targeting relationship between miR-4532 and LDOC1 in HEK-293 T cells and CD34⁺ HSCs verified by dual-luciferase reporter gene assay (*p < 0.05 vs. the co-treatment of mimic-NC and LDOC1 3′-UTR WT). c LDOC1 expression in AML-related microarray data GSE9476. d LDOC1 expression in AML retrieved from the TCGA database (the X axis indicates the sample type, and the Y axis indicates the expression value; the red box indicates the tumor sample, and the gray box indicates the normal sample; *q < 0.01). e LDOC1 expression in AML cells and CD34⁺ HSCs measured by RT-qPCR (*p < 0.05 vs. CD34⁺ HSCs). f miR-4532 expression in Molm-14 cells after transfection with miR-4532 inhibitor measured by RT-qPCR (*p < 0.05 vs. Molm-14 cells cultured with miR-4532 inhibitor). g miR-4532 expression in the exosomes from Molm-14 cells measured by RT-qPCR (*p < 0.05 vs. exosomes from inhibitor-NC-treated Molm-14 cells). h miR-4532 and LDOC1 expression in CD34⁺ HSCs after co-culture with the exosomes from transfected Molm-14 cells measured by RT-qPCR (*p < 0.05 vs. CD34⁺ HSCs treated with PBS, ^#p < 0.05 vs. CD34⁺ HSCs co-cultured with exosomes from inhibitor-NC-treated Molm-14 cells). Measurement data were described as mean ± standard deviation. Comparisons between two groups were analyzed by unpaired t test, and comparisons among multiple groups were analyzed by one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test. The cell experiment was repeated three times to obtain the mean value. miR-4532, microRNA-4532; LDOC1, leucine-zipper downregulated in cancer 1; RT-qPCR, reverse transcription quantitative polymerase chain reaction